Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.

Sander Bins,Alwin D R Huitema,Pim Laven,Samira El Bouazzaoui,Huixin Yu,Nielka van Erp,Carla van Herpen,Paul Hamberg,Hans Gelderblom,Neeltje Steeghs,Stefan Sleijfer,Ron H N van Schaik,Ron H J Mathijssen,Stijn L W Koolen

Clinical pharmacokinetics（2019）

引用 17|浏览22

暂无评分

摘要

This analysis shows that CYP3A4*22 heterozygotes have a substantial lower pazopanib clearance and that dose adjustments based on CYP3A4*22 status could be considered.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要